首页> Annals of hematology> Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies.

Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies.

导出 OA

翻译打印收藏纠错

第一作者： Luciano J,Costa

第一单位： Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham Hospital, 1802 6Th Avenue South, Birmingham, AL, 35294, USA. ljcosta@uabmc.edu.

作者： Luciano J,Costa ^[1] ; Francesca,Gay ^[2] ; Ola,Landgren ^[3] ; María-Victoria,Mateos ^[4] ; Philippe,Moreau ^[5] ; Cyrille,Touzeau ^[5] ; Franziska,Ertel ^[6] ; Ian,McFadden ^[7] ; Rani,Najdi ^[7] ; Katja,Weisel ^[8]

作者单位： Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham Hospital, 1802 6Th Avenue South, Birmingham, AL, 35294, USA. ljcosta@uabmc.edu. ^[1] AOU Città Della Salute E Della Scienza Di Torino, University of Torino, Turin, Italy. ^[2] Division of Myeloma, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA. ^[3] University Hospital Salamanca/IBSAL/CIC/Ciberonc, Salamanca, Spain. ^[4] The Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France. ^[5] Amgen GmbH, Munich, Germany. ^[6] Amgen Inc, Thousand Oaks, CA, USA. ^[7] Department of Oncology, Hematology and BMT, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. ^[8]

关键词 Daratumumab Frontline Isatuximab Monoclonal antibodies Multiple myeloma Newly diagnosed